Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: FGLL · NCAM mimetic
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Experimental peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
NCAM-mimetic signaling rationale.
Evidence and critical reading
Reported scientific and empirical uses
Cognition and neurology
NCAM mimetic promoted for neuroplasticity; confirm FGL(L) versus other variants.
Human evidence
A 24-man single-exposure phase I study assessed tolerability/PK, not sustained cognition.
Preclinical evidence
Neural signaling hypotheses require outcome trials.
Critical reading and limitations
Phase I in 24 men examined single intranasal doses/pharmacokinetics; it did not demonstrate Alzheimer treatment.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Tolerability, safety and pharmacokinetics of the FGLL peptide, a novel mimetic of neural cell adhesion molecule, following intranasal administration in healthy volunteers.
25 / 100 / 200 mg · Single exposure in separate cohorts
- Frequency
- One exposure per participant
- Duration
- 8-day study; not 8 days of repeated dosing
- Route
- Intranasal
- Context
- FGL(L), phase I, 24 healthy men. Verified mg; do not intuitively change to mcg.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID17375985 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Transient nasal irritation occurred; limited single-exposure experience cannot characterize chronic harms.
Transient nasal discomfort was reported; sample/exposure limit chronic-safety inference.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID17375985 · Open-label phase I
Healthy men.
One intranasal exposure; 8-day study.
Initial tolerability/PK, not cognitive efficacy.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 24
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
FGL · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID17375985
Anand R, Seiberling M, Kamtchoua T, Pokorny R.
October 16, 2026
- R50